Document is current
Any future updates will be listed below
-
Authors
Olafson, Kendiss https://orcid.org/0000-0002-9113-130X
Marrie, Ruth Ann
Bolton, James M.
Bernstein, Charles N.
Bienvenu, O. Joseph
Kredentser, Maia S.
Logsetty, Sarvesh https://orcid.org/0000-0003-1389-0527
Chateau, Dan
Nie, Yao
Blouw, Marcus
Afifi, Tracie O.
Stein, Murray B.
Leslie, William D.
Katz, Laurence Y.
Mota, Natalie
El-Gabalawy, Renée
Enns, Murray W.
Leong, Christine
Sweatman, Sophia
Sareen, Jitender
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (333252)
- License Information
-
More Information
Article History
Received: 7 May 2021
Accepted: 18 August 2021
First Online: 8 September 2021
Declarations
:
: JS is a consultant for UpToDare. TOA is an Associate Editor for Child Abuse & Neglect. MSK in the past 3 years received consulting income from Roche. MBS in the past 3 years has received consulting income from Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel Therapeutics, Clexio, EmpowerPharm, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Roche/Genentech. MBS has stock options in Oxeia Biopharmaceuticals and Epivario; and royalties and editorial stipends from Wiley (Anxiety and Depression), Elsevier (Biological Psychiatry) and Wolters Kluwer (UpToDate. RAM receives research funding from: CIHR, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Crohn’s and Colitis Canada, National Multiple Sclerosis Society, CMSC, the US Department of Defense, Roche, Biogen and the Government of Alberta. RAM is supported by the Waugh Family Chair in Multiple Sclerosis.
